惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

D
Docker
I
InfoQ
L
LangChain Blog
阮一峰的网络日志
阮一峰的网络日志
Y
Y Combinator Blog
博客园_首页
Martin Fowler
Martin Fowler
宝玉的分享
宝玉的分享
A
About on SuperTechFans
Apple Machine Learning Research
Apple Machine Learning Research
Vercel News
Vercel News
T
The Blog of Author Tim Ferriss
C
Check Point Blog
B
Blog RSS Feed
Cyber Security Advisories - MS-ISAC
Cyber Security Advisories - MS-ISAC
Engineering at Meta
Engineering at Meta
B
Blog
爱范儿
爱范儿
Stack Overflow Blog
Stack Overflow Blog
aimingoo的专栏
aimingoo的专栏
WordPress大学
WordPress大学
F
Fortinet All Blogs
月光博客
月光博客
GbyAI
GbyAI

WhatIs

Hims & Hers launches AI agent for lab results Twilio revamps, updates customer engagement platform CISA launches critical infrastructure cyber resilience initiative Most patients find appointment scheduling, billing overly complex Teradata's latest targets putting agentic AI into production AHA, Joint Commission launch cyber resilience program Tableau in transition as AI forces BI vendors to evolve California hospitals sue Elevance over out-of-network penalty CMS Health Tech Ecosystem adds electronic prior auth pledge Atlassian MCP updates take aim at AI token usage Leapfrog: Hospitals improved in 17 patient safety measures United promises another 30% cut to prior auths in 2026 AI outperforms docs on clinical reasoning, but not ready for solo work ServiceNow's Autonomous CRM takes aim at Salesforce ServiceNow reintroduces itself as an AI 'security company' New Tableau leader talks vendor's evolution in era of AI Deloitte warns of a "bubble effect" caused by the GLP-1 boom Tableau repositions for AI, unveils new knowledge layer IBM Bob AI coding agent ships, HashiCorp AIOps previewed DOJ forms West Coast Strike Force to stop healthcare fraud Most people benefit from the ACA's free preventive services SAP acquisitions of Dremio, Prior Labs target AI development Bridging the gap: Legacy tools gain enterprise AI support Amazon Connect Talent: AWS enters AI interviewing market AHA, West Health launch health tech adoption initiative How are states preparing for Medicaid work requirements? Medical device security improves, but cyberattacks remain pervasive Weekly news roundup: Musk vs. Altman, Google’s Pentagon AI deal, China and EU hit Meta Skin substitute spending driven by patients, products, prices Clinical AI company Aidoc snags $150M in new funding
Amazon Pharmacy adds Lilly's obesity pill with same-day d...
Alivia Kaylor, MSc · 2026-04-10 · via WhatIs

StarLineArts/istock via getty im

Amazon's pharmacy now sells Eli Lilly's recently approved weight loss pill at in-office kiosks and offers same-day delivery online.

Amazon is expanding its push into cardiometabolic care. The tech giant's online pharmacy now provides same-day delivery for Eli Lilly's recently approved GLP-1 obesity drug, Foundayo, and sells the pill at medication-dispensing kiosks inside select One Medical clinics.

This move leverages Amazon's delivery logistics network to expand access to nearly 3,000 cities and towns, with plans to reach another 1,500 by the end of the year, according to the company. Patients with a valid prescription can order the drug online and see real-time availability and pricing.

"Amazon Pharmacy is reducing barriers for customers to access new weight management treatments like Foundayo," Tanvi Patel, vice president and general manager of Amazon Pharmacy, said.

In rural communities, where the nearest pharmacy may be more than an hour away, Amazon said it will deliver prescriptions within 1–3 days of ordering, whereas other mail-order delivery services typically take 5–10 days.

Oral GLP-1 drugs can be stored at room temperature, which is an advantage pills have over injectable versions on the market. Injectable GLP-1 therapies, like Eli Lilly's Zepound and Novo Nordisk's Wegovy, are not stocked in pharmacy kiosks because they need to be kept cold.

"Medications can best fulfill their promise when patients can actually access them," Laura Steele, Group Vice President of U.S. Cardiometabolic Health at Eli Lilly, also said. "If prescribed, patients may be able to have Foundayo on their doorstep the same day or walk out of their doctor's office with it in-hand in Los Angeles -- eliminating the waiting and uncertainty that patients may face when starting their treatment journey."

For patients with insurance coverage, Foundayo costs around $25 per month on the Amazon Pharmacy website. Self-pay patients can buy the drug starting at $149 for the lowest dose, with higher doses costing $199–$349 per month.

Amazon Pharmacy has delivered GLP-1 medications since 2021. Amazon says its customers have saved more than $200 million through its automatic coupon program to date, with GLP-1 medications representing the largest savings category.

Manufacturer-sponsored coupons are automatically applied at checkout, though patients must refill within 45 days of receiving their previous prescription to remain eligible for discounted pricing.

Other companies have also expanded access and started selling the newly approved drug, including WeightWatchers, which is offering same-day delivery through Amazon.

Patients with a valid prescription can also order Foundayo from online providers Ro and GoodRx, as well as Lilly's direct-to-consumer pharmacy, LillyDirect.

Foundayo -- previously better known as orforglipron -- won FDA approval as a once-daily tablet that can be taken at any time without food or water restrictions. The drug is indicated for adults with obesity or overweight accompanied by weight-related medical conditions. At 72 weeks, patients on the highest dose of Lilly's drug lost an average of 12.4% of their body weight in the phase 3 Attain-1 trial.

In comparison, Novo's Wegovy pill, which was first to hit the market in January, must be taken first thing in the morning on an empty stomach.

In a cross-trial comparison published a day after Foundayo was approved, Novo reported its obesity pill led to 3.2% greater weight loss and significantly fewer discontinuations due to gastrointestinal side effects.

According to Wegovy's phase 3 Oasis 4 trial, patients taking the highest dose lost an average of 13.6% over 64 weeks.

Novo's pill is priced similarly to Lilly's for those paying out of pocket, with the lowest dose starting at $149 a month.

Alivia Kaylor is a scientist and the senior site editor of Pharma Life Sciences.

Dig Deeper on Pharmaceuticals